KOD Kodiak Sciences Inc

14.31
+0.26  (+2%)
Previous Close 14.05
Open 14.05
Price To Book 6.59
Market Cap 528,208,674
Shares 36,911,857
Volume 16,539
Short Ratio
Av. Daily Volume 196,154

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial planned 2H 2019 with interim data 2020 and final data 2021. Phase 1b data to be presented at ASRS meeting July 26-30, 2019.
KSI-301
Wet age-related macular degeneration (AMD)
Phase 2 trial planned 2H 2019.
KSI-301
Diabetic macular edema (DME)
Phase 1b open label data due throughout 2019.
KSI-301
Diabetic macular edema (DME); Wet Age-related Macular Degeneration

Latest News

  1. Kodiak Sciences Inc. (KOD) Shares March Higher, Can It Continue?
  2. Kodiak Sciences to Present at the Jefferies 2019 Healthcare Conference
  3. How Much Of Kodiak Sciences Inc. (NASDAQ:KOD) Do Insiders Own?
  4. Kodiak Sciences Announces First Quarter 2019 Financial Results and Recent Business Highlights
  5. Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference 2019
  6. Kodiak Sciences Announces Presentations at ARVO 2019 Annual Meeting
  7. Kodiak Sciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
  8. Kodiak Sciences to Present at the Barclays Global Healthcare Conference
  9. The Zacks Analyst Blog Highlights: Microsoft, Kodiak Sciences, General Motors and Procter & Gamble
  10. Wall Street Takes Notice of These 4 Stocks - Should You?
  11. The Smartest People on Wall Street Are Buying These 3 Stocks -- Should You Follow?
  12. Kodiak Sciences Announces Upcoming Presentation of KSI-301 12-Week Phase 1a Study Data at Angiogenesis, Exudation, and Degeneration 2019 Meeting
  13. Have Insiders Been Buying Kodiak Sciences Inc. (NASDAQ:KOD) Shares?
  14. Kodiak Sciences Added to Russell 2000®, 3000® and Microcap® Indexes
  15. Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate
  16. This year's Bay Area IPO batch remains up 44% despite market turbulence
  17. Kodiak Sciences Announces Third Quarter 2018 Financial Results and Recent Business Highlights
  18. Strong IPO pace continued in October but some cracks are showing
  19. Here are 10 Bay Area accelerators ranked as best in the U.S.